Inventiva is a clinical-stage biopharmaceutical company focused on lanifibranor, an investigational once-daily oral pan-PPAR agonist being developed for metabolic dysfunction–associated steatohepatitis (MASH) with liver fibrosis. The candidate is designed to engage PPAR α, δ, and γ pathways linked to fat accumulation, inflammation, and fibrosis in the liver. The company’s R&D effort is concentrated on this late-stage MASH program rather than a broad commercial product portfolio.
| Year | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| 2022 | 12.2 | — | -54.3 | — |
| 2023 | 17.5 | 43.5% | -110.4 | — |
| 2024 | 9.2 | -47.4% | -184.2 | — |
| 2025 | 4.5 | -51.3% | -354.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Scholastic Corporation (SCHL), Donegal Group Inc. (DGICA), NANO Nuclear Energy Inc. (NNE), Qfin Holdings, Inc. (QFIN), Docebo Inc. (DCBO), MidCap Financial Investment Corporation (MFIC)